3、公司实施员工持股计划的目的在于充分调动核心骨干员工的积极性，有 效地将股东利益、公司利益和员工个人利益紧密结合在一起，提高员工凝聚力和 公司竞争力，建立和完善利益共享机制，促进公司健康可持续发展。 通化东宝药业股份有限公司 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）董事会薪 酬与考核委员会根据《公司法》《证券法》《关于上市公司实施员工持股计划试 点的指导意见》(以下简称"《指导意见》")《上海证券交易所上市公司自律监 管指引第1号——规范运作》(以下简称"《规范运作》")等相关法律法规、规 范性文件及《公司章程》的有关规定，在认真审阅《通化东宝研发生产系统员工 持股计划(草案）》及其摘要的基础上，经充分、全面的讨论与分析，依据相关规 定，就公司研发生产系统员工持股计划相关事项发表核查意见如下： 1、公司不存在《公司法》《证券法》《指导意见》《规范运作》等法律法 规、规范性文件规定的禁止实施员工持股计划的情形；《通化东宝研发生产系统员 工持股计划(草案）》及其摘要符合《公司法》《证券法》《指导意见》等有关法律 法规、规范性文件及《公司章程》的规定，不存在损害公司及全体股东利益的情 形。 2、 ...

Group 1 - The company Tonghua Dongbao (SH 600867) announced that its 11th Board of Directors' 20th meeting was held via telecommunication on November 28, 2025, to review the proposal for the 2025 fourth extraordinary shareholders' meeting [1] - For the first half of 2025, the company's revenue composition was as follows: pharmaceutical industry accounted for 98.59%, other businesses for 1.27%, and real estate for 0.14% [1] - As of the report date, Tonghua Dongbao's market capitalization was 17.2 billion yuan [1]

Core Viewpoint - Tonghua Dongbao (600867.SH) has announced a draft employee stock ownership plan (ESOP) aimed at raising a maximum of 30.73 million yuan, involving up to 122 employees [1] Group 1: Employee Stock Ownership Plan Details - The ESOP will involve a maximum of 122 participants and aims to raise a total of 30.73 million yuan, with each unit priced at 1 yuan [1] - The total number of shares to be acquired under the ESOP will not exceed 7 million shares, representing 0.357% of the company's current total equity [1] - The initial portion of shares to be acquired will not exceed 6.37 million shares [1] Group 2: Share Pricing and Acquisition - The acquisition price for the repurchased shares under the ESOP is set at 4.39 yuan per share, which is subject to a minimum price based on previous trading averages [1] - The minimum price for the shares will be the higher of 50% of the average trading price of 8.77 yuan per share on the trading day before the announcement or 50% of the average trading price of 8.52 yuan per share over the preceding 120 trading days [1]

Core Viewpoint - Tonghua Dongbao (600867.SH) has disclosed a draft for an employee stock ownership plan (ESOP), aiming to raise a maximum of 30.73 million yuan, with participation limited to no more than 122 employees [1] Summary by Relevant Sections Employee Stock Ownership Plan - The ESOP plans to raise a total amount of up to 30.73 million yuan, with each share priced at 1 yuan [1] - The total number of shares to be acquired under the ESOP does not exceed 7 million shares, representing 0.357% of the company's current total equity [1] - The initial portion of shares to be acquired is capped at 6.37 million shares [1] Share Acquisition Price - The acquisition price for the repurchased shares under the ESOP is set at 4.39 yuan per share, which is not lower than the higher of the following two prices: 1. 50% of the average trading price of the company's stock on the trading day prior to the announcement of the ESOP draft, which is 8.77 yuan per share 2. 50% of the average trading price over the 120 trading days prior to the announcement, which is 8.52 yuan per share [1]

通化东宝药业股份有限公司 总裁工作细则 第一章 总则 第一条 为了进一步完善公司法人治理结构，提高总裁工作质量，规范总裁 工作，保证总裁依法行使职权，忠实履行职责，促进日常经营管理活动有效开展， 根据《公司法》《上市公司治理准则》《上海证券交易所股票上市规则》及公司 章程的有关规定，制定本工作细则。 第二条 公司设总裁。总裁对董事会负责，主持公司日常生产经营和管理工 作，组织实施董事会决议。 第三条 本工作细则所称高级管理人员，是指公司的总裁、副总裁、董事会 秘书、财务负责人以及《公司章程》规定的其他高级管理人员。 第二章 任职资格及任免程序 第四条 公司设总裁 1 名，由董事会聘任或解聘，总裁可由董事兼任；设副 总裁若干名、董事会秘书 1 名、财务负责人（总会计师） 1 名，由总裁提名， 由董事会聘任或解聘。 第五条 总裁任职应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营 管理能力； （二）具有调动员工积极性的领导能力，建立合理的组织机构、协调各种内 外关系和统揽全局的能力； （六）被中国证监会采取证券市场禁入措施，期限未满的； （三）具有一定年限的企业管理或经济工作 ...

Core Insights - The article highlights the successful international approval of Liraglutide injection by Tonghua Dongbao Pharmaceutical Co., Ltd. in Peru, marking a significant milestone in the company's global expansion strategy in the GLP-1 product category [4] - Liraglutide, a GLP-1 analog, is recognized for its efficacy in improving blood sugar levels, cardiovascular protection, and weight loss, gaining global acceptance [4] Market Growth and Strategy - The International Diabetes Federation (IDF) projects that the number of adults aged 20-79 with diabetes will reach 589 million in 2024, with a prevalence rate of 11.1%, and is expected to rise to 853 million by 2050, indicating a growing market for diabetes treatments [6] - The company, in collaboration with Sinovac Biotech, is targeting emerging markets with high diabetes prevalence, covering 17 countries across Latin America, the Middle East and North Africa, Southeast Asia, and South Africa [6] Product Development and Internationalization - The company has achieved significant progress in international registrations for multiple products, including Liraglutide and insulin formulations, with approvals in Indonesia, Uzbekistan, and other emerging markets [7] - The internationalization strategy is set to accelerate, aiming to expand overseas sales and provide accessible diabetes treatment options to a broader patient base [7]

Market Overview - The biopharmaceutical sector increased by 0.36% compared to the previous trading day, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Jindike (688670) saw a closing price of 30.90, with a significant increase of 20.00% and a trading volume of 192,400 shares, amounting to a transaction value of 572 million [1] - Rongchang Bio (688331) closed at 92.25, up 5.43%, with a trading volume of 68,800 shares and a transaction value of 635 million [1] - Sanofi (688336) closed at 68.39, up 4.59%, with a trading volume of 74,400 shares and a transaction value of 510 million [1] - Other notable performers include Olin Bio (616889) with a 4.43% increase and Hualan Bio (301207) with a 3.21% increase [1] Fund Flow Analysis - The biopharmaceutical sector experienced a net inflow of 20.94 million from institutional investors, while retail investors saw a net outflow of 57.02 million [2] - Jindike had a net inflow of 57.00 million from institutional investors, despite a net outflow of 19.76 million from retail investors [3] - Rongchang Bio also saw a net inflow of 32.94 million from institutional investors, with retail investors withdrawing 25.48 million [3]

Core Viewpoint - The successful completion of the GMP audit for the liraglutide injection by Tonghua Dongbao and its partner Sinovac Biotech marks a significant step in the company's internationalization strategy and paves the way for market entry in Brazil and expansion in South America [1][2]. Group 1: Company Developments - Tonghua Dongbao and Sinovac Biotech have collaborated to obtain exclusive commercialization rights for liraglutide injection in 17 emerging markets [1]. - The GMP audit conducted by Brazil's ANVISA was based on PIC/S guidelines, covering the entire production and quality management chain, and resulted in a "zero defect" outcome [1][2]. - The successful audit is seen as a key breakthrough for the company's international strategy, facilitating rapid entry into the Brazilian market [2]. Group 2: Market Context - Brazil has seen an increase in diabetes prevalence, with 16.62 million patients aged 20-79 and a prevalence rate of 10.7% [2]. - The country has established itself as a benchmark in the emerging pharmaceutical market since joining PIC/S in 2021, known for its stringent GMP standards [2]. - The company plans to accelerate the commercialization of more high-value products globally, enhancing treatment options for patients and driving long-term growth [2].

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]

Core Viewpoint - Tonghua Dongbao is focusing on expanding its product pipeline in diabetes and endocrine metabolic diseases, achieving significant revenue growth and international market expansion in 2025 [2][3][4]. Financial Performance - In the first three quarters of 2025, the company reported revenue of 2.18 billion yuan, a year-on-year increase of 50.55%, and a net profit of 1.202 billion yuan, compared to a loss of 66.37 million yuan in the same period last year [2]. - In Q3 2025, the company achieved revenue of 806 million yuan, a year-on-year growth of 13.9%, and a net profit of 984 million yuan, representing a staggering increase of 499.86% [2]. Product Development and Market Expansion - The sales volume of insulin analogs doubled year-on-year in the first three quarters of 2025, with revenue from these products surpassing human insulin, becoming the largest revenue contributor for the company [2]. - The company is expanding its research pipeline to include indications beyond diabetes, such as obesity and non-alcoholic steatohepatitis (NASH), as well as other endocrine metabolic diseases like gout and hyperuricemia [2]. International Strategy - In H1 2025, overseas revenue reached 110 million yuan, a year-on-year increase of approximately 187%, surpassing the total revenue for the previous year, indicating the effectiveness of the internationalization strategy [3]. - The company has made significant progress in international registrations, with insulin products approved in five emerging markets and ongoing BLA submissions for insulin products in the U.S. [4]. - The company is focusing on the U.S. market due to the large patient base and significant market opportunities, collaborating with Jianyou Co. to share risks and leverage expertise [5][6]. Future Outlook - The company aims to drive growth through a dual strategy of "innovation + internationalization," solidifying its leadership in diabetes treatment while expanding its product registrations in both developed and emerging markets [6].